Pfizer Inc. $PFE Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 146.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 299,137 shares of the biopharmaceutical company’s stock after acquiring an additional 177,627 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Pfizer were worth $8,400,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. YANKCOM Partnership purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $28,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Abound Financial LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research report on Tuesday, June 9th. Guggenheim lifted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Wolfe Research restated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $28.82.

Pfizer Price Performance

PFE opened at $24.29 on Friday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company’s 50-day moving average price is $25.63 and its 200 day moving average price is $26.23. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.